How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Sell
10
DTIL Quote, Financials, Valuation and Earnings
Last price:
$4.34
Seasonality move
:
-22.75%
Day range:
$4.38 - $4.65
52-week range:
$3.61 - $11.09
Dividend yield:
0%
P/E ratio:
3.41x
P/S ratio:
0.69x
P/B ratio:
1.00x
Volume:
138K
Avg. volume:
402.8K
1-year change:
-56.54%
Market cap:
$49.3M
Revenue:
$68.7M
EPS (TTM):
-$2.53
Analysts' Opinion
-
Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.50, Precision BioSciences has an estimated upside of 585.39% from its current price of $4.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $4.45.
Fair Value
-
According to the consensus of 2 analysts, Precision BioSciences has 585.39% upside to fair value with a price target of $30.50 per share.
DTIL vs. S&P 500
-
Over the past 5 trading days, Precision BioSciences has underperformed the S&P 500 by -0.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Precision BioSciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Precision BioSciences revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Precision BioSciences reported revenues of $29K.
Earnings Growth
-
Precision BioSciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Precision BioSciences reported earnings per share of -$2.21.
Enterprise value:
-5.5M
EV / Invested capital:
--
Price / LTM sales:
0.69x
EV / EBIT:
-1.63x
EV / Revenue:
-0.11x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-1.08x
Gross Profit (TTM):
--
Return On Assets:
-14.38%
Net Income Margin (TTM):
-42.99%
Return On Equity:
-38.91%
Return On Invested Capital:
-27.87%
Operating Margin:
-76248.28%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $30.6M | $57.5M | $51.1M | $17.6M | $29K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$69.7M | -$34.6M | -$44.1M | -$4.2M | -$22.1M | |
| EBITDA | -$69.5M | -$10.3M | -$16.6M | $10.6M | -$19.5M | |
| Diluted EPS | -$34.95 | -$7.59 | -$2.53 | $1.70 | -$2.21 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $219.1M | $134.1M | $169M | $160.8M | $82.1M | |
| Total Assets | $262.3M | $181.4M | $204.5M | $184.7M | $124.4M | |
| Current Liabilities | $63.8M | $29.1M | $46.9M | $33.3M | $12.4M | |
| Total Liabilities | $203.5M | $111.7M | $164.3M | $147.5M | $75.1M | |
| Total Equity | $58.8M | $69.7M | $40.2M | $37.2M | $49.3M | |
| Total Debt | -- | $2.5M | $22.3M | $22.5M | $22.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.3M | -$71.6M | -$58.5M | -$19M | -$19.1M | |
| Cash From Investing | -$3.2M | $6.5M | -$503K | -$26K | -$314K | |
| Cash From Financing | $93.5M | $44.7M | $21M | $40.1M | $10.7M | |
| Free Cash Flow | -$51.6M | -$73.3M | -$59M | -$19.1M | -$19.4M | |
DTIL
Sector
Market Cap
$49.3M
$34.5M
Price % of 52-Week High
40.13%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
-41.31%
-1.01%
1-Year Price Total Return
-56.54%
-35.15%
Beta (5-Year)
1.428
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.53
200-day SMA
Sell
Level
$5.80
Bollinger Bands (100)
Sell
Level
4.54 - 5.38
Chaikin Money Flow
Buy
Level
296.1K
20-day SMA
Sell
Level
$4.51
Relative Strength Index (RSI14)
Sell
Level
46.09
ADX Line
Buy
Level
21.23
Williams %R
Neutral
Level
-54.7368
50-day SMA
Sell
Level
$4.82
MACD (12, 26)
Buy
Level
1.20
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
380K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.2938)
Sell
CA Score
(Annual)
Level (-1.14)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-4.193)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Stock Forecast FAQ
In the current month, DTIL has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DTIL average analyst price target in the past 3 months is $30.50.
-
Where Will Precision BioSciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Precision BioSciences share price will rise to $30.50 per share over the next 12 months.
-
What Do Analysts Say About Precision BioSciences?
Analysts are divided on their view about Precision BioSciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Precision BioSciences is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Precision BioSciences's Price Target?
The price target for Precision BioSciences over the next 1-year time period is forecast to be $30.50 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DTIL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Precision BioSciences is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DTIL?
You can purchase shares of Precision BioSciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Precision BioSciences shares.
-
What Is The Precision BioSciences Share Price Today?
Precision BioSciences was last trading at $4.34 per share. This represents the most recent stock quote for Precision BioSciences. Yesterday, Precision BioSciences closed at $4.45 per share.
-
How To Buy Precision BioSciences Stock Online?
In order to purchase Precision BioSciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
78
SBET alert for Jul 16
SharpLink Gaming [SBET] is up 33.9% over the past day.
Buy
75
MP alert for Jul 16
MP Materials [MP] is down 0.21% over the past day.
Sell
38
NAIL alert for Jul 16
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 1.8% over the past day.
